Teva Pharma (TEVA): Upcoming Catalysts

August 15, 2016 8:31 AM EDT
Get Alerts TEVA Hot Sheet
Price: $33.75 --0%

Rating Summary:
    19 Buy, 20 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 10 | Down: 16 | New: 54
Trade TEVA Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Guggenheim analyst Louise Chen, reiterated her Buy rating on shares of Teva Pharma (NYSE: TEVA) and highlighted some upcoming catalysts.

After closing the AGN generics deal earlier this month, TEVA plans to provide investors with an overview of its generics business in September. The analyst expects TEVA to give more details on the generics pipeline, integration, and synergy capture. She believes this could give the Street more confidence in TEVA's generics platform and its ability to mitigate risk from Copaxone. She does not expect generic competition until 2018+. Later this month, TEVA will receive two decisions on the IPR challenge for Copaxone 40mg, about whether three patents have been invalidated and if a fourth will be considered for IPR. However, the decision on the first three patents can be appealed, and even if IPR is instituted on the fourth, a decision may not come until 2018. There is also a parallel PIV process involving 5 companies in motion, and the trial starts 9/26. She expects a decision by 1Q17 when the 30-month stays expire, but if the decision is unfavorable, TEVA can appeal, which could take until 2018. A generic could still launch at-risk upon approval, but FDA has not approved any generics yet

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $53.86 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Louise Chen, Guggenheim

Add Your Comment